Krystal Biotech (LAUR) Downgraded by Zacks Investment Research to Sell

Krystal Biotech} stock has undergone multiple analysts rating changes in the recent past.  Krystal Biotech Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Krystal Biotech (LAUR) Downgraded by Zacks Investment Research to Sell